Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lestaurtinib in Myelofibrosis
NCT00668421Phase 2Unknown
- Start
- Apr 2008
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lestaurtinib in myelofibrosis (MF). Primary endpoints: Maximum Tolerated Dose at 2 years and Reduction in JAK2 V617F Allele Frequency at 2 years. Status: unknown.
02
Drugs
lestaurtinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT00668421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00668421.